alexa
Reach Us +44-7482877764
Glycosaminoglycan Derived Nanocarriers: Exploiting Natural Biopolymers For Tumor Targeting And Mitigating Immune Activation | 91544
ISSN: 2169-0022

Journal of Material Sciences & Engineering
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Glycosaminoglycan derived nanocarriers: Exploiting natural biopolymers for tumor targeting and mitigating immune activation

4th International Conference on Polymer Chemistry

Oommen P Oommen

Tampere University of Technology, Finland

Keynote: J Material Sci Eng

DOI: 10.4172/2169-0022-C10-118

Abstract
Glycoaminoglycans, such as hyaluronic acid (HA) and chondroitin sulfate (CS), are natural biopolymers present in the extracellular matrix (ECM) that have generated great interest for designing drug delivery systems. As HA and CS possess a unique ability to target CD44 receptors that are overexpressed in malignant solid tumors (nearly 6-8 folds higher than normal tissues), they have been used for anticancer therapeutics. Moreover, hyaluronidase, a ubiquitious enzyme that degrade these polymers are expressed highly in these malignant tumors, resulting in rapid turnover of these polymers in tumor tissue. We have recently engineered HA and CS derived soft nanocarriers and compared their tumor targeting properties and evaluated their role in the activation of complement and coagulation cascade reactions in human blood. We found that CS undergoes faster cellular uptake properties than HA. CS being a sulfated polymer, unlike HA, demonstrated activation of complement at higher concentrations. Thereafter, we engineered CS coated gold nanoparticles following a green chemistry strategy. Doxorubicin (DOX) a clinically used antineoplastic agent was conjugated to the CS-gold nanoparticle (CS-Au-DOX) via pH-responsive hydrazone linkages, which yielded sustained drug release profile at acidic pH. Unlike other colloidal gold particles, CS-Au- DOX was extremely stable and could be stored as a lyophilized powder. The CS-Au-DOX exhibited higher toxicity towards CD44 overexpressing human colon cancer cells (HCT116 and GP5D) as compared to free DOX. Interestingly, CS-Au-DOX also overcame multidrug resistance induced by p-glycoprotein overexpression in ovarian cancer cell line A2780. The confocal laser scanning microscopy images clearly showed nuclear transport of these DOX loaded nanoparticles. We incubated free DOX and CS-Au-DOX with non-anticoagulated human whole blood to estimate the thromboinflammation and platelet aggregation. We observed that doxorubicin (DOX) induced acute platelet toxicity and trigger coagulation cascade in human whole blood model. CS-Au-DOX on the other hand mitigated DOX mediated toxicity to human platelets and suppressed thromboinflammation. Our studies reveal that GAG derived nanoparticles offer new avenues to design innocuous drug delivery system that could mitigate drug mediated side effects.
Biography

Oommen P Oommen has received his PhD in Organic Chemistry from Indian Institute of Technology, Bombay. He then moved to Uppsala University, Sweden to pursue his Post-Doctoral studies. In 2016, he joined Tampere University of Technology, Finland as an Assistant Professor where he leads a multidisciplinary team of chemists, molecular biologists and material scientists. His research interests are in the fields of designing functional polymers and biomaterials for tissue engineering, drug delivery and nucleic acid therapeutics. He authored several peer reviewed articles and book chapters. He has also filed several patents and is a Co-founder of a spin-off called ‘Uppsala Therapeutics AB’.

E-mail: [email protected]

Top